Skip to main content
. 2023 Dec 17;30(4):e14524. doi: 10.1111/cns.14524

FIGURE 8.

FIGURE 8

HDAC2 inhibition suppressed NF‐κB‐mediated inflammation and ferroptosis of DRG in vitro. (A) Cell viability of DRG treated with Erastin and HDAC2‐KD or without HDAC2‐KD was assessed by CCK8. *p < 0.05; **p < 0.01. (B and C) Cell viability of DRG treated with Erastin and HDAC2‐KD or without HDAC2‐KD was assessed by FDA staining. *p < 0.01; **p < 0.001. (D and E) ROS level, MDA content of DRG treated with Erastin, and HDAC2‐KD or without HDAC2‐KD were assessed by Elisa. *p < 0.01; **p < 0.001. (F) Ferroptosis of DRG treated with Erastin and HDAC2‐KD or without HDAC2‐KD was assessed by TEM. The arrows indicated the morphological changes. (G‐I) The mRNA level of IL‐1β, IL‐6, and TNF‐α in different groups was assessed by qRT‐PCR. *p < 0.05; **p < 0.01; ***p < 0.001. (J–K) Western blotting and semi‐quantifications for p‐P65, P65, p‐IκB, and IκB protein in different groups. *p < 0.05; **p < 0.01; ***p < 0.001.